Search

Search Results
Results 6441 - 6450 of 6667 for Cancer pain
  • EpiCept provides business update and fourth-quarter financial highlights
    News - 25 Feb 2010
    EpiCept Corporation today announced operating and financial results for the fourth quarter and year ended December 31, 2009, and provided an update on Ceplene® and several of the Company’s key product...
  • Meda publishes 2009 year-end report
    News - 16 Feb 2010
    “The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”
  • Paxtine
    Drug - 2 Apr 2026
    Consumer Medicine Information (CMI) about Paxtine intended for persons living in Australia.
  • Apixaban-APX
    Drug - 31 Mar 2026
    Consumer Medicine Information (CMI) about Apixaban-APX intended for persons living in Australia.
  • Shingrix
    Drug - 31 Mar 2026
    Consumer Medicine Information (CMI) about Shingrix intended for persons living in Australia.
  • Rabeprazole Viatris
    Drug - 30 Mar 2026
    Consumer Medicine Information (CMI) about Rabeprazole Viatris intended for persons living in Australia.
  • Trandolapril Viatris
    Drug - 19 Mar 2026
    Consumer Medicine Information (CMI) about Trandolapril Viatris intended for persons living in Australia.
  • Trimethoprim Viatris
    Drug - 19 Mar 2026
    Consumer Medicine Information (CMI) about Trimethoprim Viatris intended for persons living in Australia.
  • Alprim
    Drug - 19 Mar 2026
    Consumer Medicine Information (CMI) about Alprim intended for persons living in Australia.
  • Noxafil concentrated injection
    Drug - 16 Mar 2026
    Consumer Medicine Information (CMI) about Noxafil concentrated injection intended for persons living in Australia.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback